Alterations of the endocannabinoid system in an animal model of migraine: Evaluation in cerebral areas of rat

Abstract

Endocannabinoids are involved in the modulation of pain and hyperalgesia. In this study we investigated the role of the endocannabinoid system in the migraine model based on nitroglycerin-induced hyperalgesia in the rat. Male rats were injected with nitroglycerin (10 mg/kg, i.p.) or vehicle and sacrificed 4 h later. The medulla, the mesencephalon and the hypothalamus were dissected out and utilized for the evaluation of activity of fatty acid amide hydrolase (that degrades the endocannabinoid anandamide), monoacylglycerol lipase (that degrades the endocannabinoid 2-arachidonoylglycerol), and binding sites specific for cannabinoid (CB) receptors. The findings obtained show that nitroglycerin-induced hyperalgesia is associated with increased activity of both hydrolases and increased density of CB binding sites in the mesencephalon. In the hypothalamus we observed an increase in the activity of fatty acid amide hydrolase associated with an increase in density of CB binding sites, while in the medulla only the activity of fatty acid amide hydrolase was increased. Anandamide also proved effective in preventing nitroglycerin-induced activation (c-Fos) of neurons in the nucleus trigeminalis caudalis. These data strongly support the involvement of the endocannabinoid system in the modulation of nitroglycerin-induced hyperalgesia, and, possibly, in the pathophysiological mechanisms of migraine.

Keywords

Nitroglycerin migraine endocannabinoids FAAH MAGL cannabinoid binding

Introduction

The endocannabinoid system has been demonstrated to be tonically active in several pathological conditions. Alterations of endocannabinoid levels have been found in animal models of pain, neurological diseases and inflammatory conditions (1,2). Endocannabinoids can induce antinociceptive effects in models of acute or chronic pain through type-1 cannabinoid (CB1) receptors located on neurons, both within and outside the brain and spinal cord (3). In a recent study, it was reported that anandamide [N-arachidonoylethanolamine (AEA)], an endogenous ligand of CB receptors, is capable of inhibiting neurogenic dural vasodilation induced by calcitonin gene-related peptide (CGRP) or nitric oxide (NO) in an animal model of migraine (4). Conversely, an increase of AEA degradation was seen in platelets of migrainous women, therefore providing an additional biochemical explanation for a higher prevalence of migraine in women than in men (5). Systemic administration of the NO donor nitroglycerin (NTG) has been used extensively as an animal model of migraine pain because NTG provokes spontaneous-like migraine attacks in migraine sufferers, and induces a condition of hyperalgesia in the rat through the activation of spinal and brain structures involved in nociception (6,7). In the brain, endocannabinoids may function as retrograde messengers to modulate neuronal physiology of presynaptic CB1 receptors (8,9). AEA is mainly metabolized by fatty acid amide hydrolase (FAAH) (10), whereas 2-arachidonoylglycerol (2-AG), another endogenous agonist of CB receptors, is mainly metabolized by monoacylglycerol lipase (MAGL) (11). Additionally, both endocannabinoids may be metabolized by type-2 cyclooxygenase (12). Endocannabinoids distribution does not seem to match exactly that of CB binding sites (13), therefore suggesting either that these compounds are not essentially produced near their molecular targets, or that they may play functional roles in addition to the activation of CB receptors.

In order to elucidate further the role of endocannabinoids in migraine, we investigated the changes in the biochemical mediators degrading endogenous cannabinoids, as well as the density of sites that bind endocannabinoids in specific areas of the rat brain in the migraine model based on NTG-induced hyperalgesia in the rat. In addition, in order to better contextualize these data within the pathophysiological mechanisms underlying cephalic pain, we also evaluated the effect of AEA on NTG-induced expression of c-Fos protein in the nucleus trigeminal caudalis (NTC), a pivotal area for the modulation of nociceptive processing in the cranial region.

Materials and methods

Experimental groups

Adult male Sprague-Dawley rats weighing 180–220 g were used in the present investigation. The Helsinki declaration and the International Association for the Study of Pain's guidelines for pain research in animals (1983) were followed. Rats were housed in plastic boxes in groups of three with water and food available ad libitum and were kept on a 12 : 12 h light–dark cycle. All animals were acclimatized for 2 h before treatment. Rats were subdivided into two groups formed by four to six animals each and were treated with 10 mg/kg of NTG (NTG group) or vehicle (Control group), and were sacrificed 4 h later by decapitation. Medulla, mesencephalon and hypothalamus were dissected out and utilized for biochemical analyses (14,15). Two additional groups of animals were treated with NTG or vehicle and utilized for immunohistochemical staining of c-Fos protein in the medulla (see below). Finally, two groups of animals were treated with NTG or vehicle and injected with 1% formalin (100 µl, intraplantar) 4 h later, to confirm the longlasting hyperalgesic state induced by NTG in rats. Total number of flinches/shakes were counted for 1-min periods from 1 to 5 min (Phase I) and, subsequently, for 1-min periods at 5-min intervals during the following 10–60 min (Phase II) after formalin injection (16).

Reagents

The synthetic cannabinoid 5-(1,10-dimethyheptyl)-2-[1R,5R-hydroxy-2R-(3-hydroxypropyl)-cyclohexyl]phenol (CP55.940) was purchased from Sigma Chemical Co. (St Louis, MO, USA). [³H]2-Oleoylglycerol ([³H]2-OG, 20 Ci/mmol) was from ARC (St Louis, MO, USA). [³H]AEA (205 Ci/mmol) and ³H-CP55.940 (126 Ci/mmol) were purchased from Perkin Elmer Life Sciences (Boston, MA, USA).

Enzyme assays

The hydrolysis of AEA by FAAH in tissue homogenates was assessed by measuring the release of ³H-arachidonic acid from 10 µM ³H-AEA, through reverse-phase high-performance liquid chromatography, as reported (14,15). MAGL activity was assayed in supernatants from tissue homogenates, obtained at 39 000 g and incubated with 10 µM ³H-2-OG at 37°C for 30 min (11). The reaction was stopped with a mixture of chloroform/methanol (2 : 1, v/v), and the release of ³H-glycerol in the aqueous phase was measured in a β-counter (Perkin Elmer Life Sciences). Both FAAH and MAGL activities were expressed as pmol product per min per mg protein.

Binding to cannabinoid receptors

For CB binding studies, membrane fractions were prepared from cerebral area extracts as reported (14,15), quickly frozen in liquid nitrogen and stored at −80°C for no longer than 1 week. These membrane fractions were used in rapid filtration assays with the synthetic cannabinoid ³H-CP55.940 (400 pM), as described previously (14,15). Unspecific binding to CB receptors was assessed in the presence of 1 µM ‘cold’ agonist (14,15). Receptor binding was expressed as fmol ³H-agonist bound per mg protein.

Immunohistochemistry

Anandamide (Sigma), suspended in 4% Tween 80, was injected intraperitoneally at a dose of 20 mg/kg. Male Sprague-Dawley rats were injected with systemic AEA 30 min before NTG administration or vehicle and sacrificed 4 h later. Animals were anaesthetized and perfused transcardially with saline and 270 ml of ice-cold 4% paraformaldehyde 4 h after NTG/saline administration. Brainstems were removed, post-fixed for 12 h in the same fixative and subsequently transferred in solutions of sucrose at increasing concentrations (up to 30%) during the following 72 h. Brains were cut at 50 µm on a freezing sliding microtome. c-Fos expression in the rat brain was detected by means of the immunohistochemical technique with a rabbit polyclonal antiserum directed against c-Fos protein (residues 4–17 of human c-Fos). Tissue sections were incubated for 48 h at 4°C with the c-Fos antibody (Oncogene, Cambridge, MA, USA). After thorough rinsing in buffer, sections were processed with the avidin–biotin technique, using a commercial kit. Cells positively stained for c-Fos were visualized with nickel-intensified 3′,3′-diaminobenzidine tetrahydrochloride. After staining, sections were rinsed in buffer, mounted onto glass slides, air-dried and coverslipped.

Statistical evaluation

Comparisons between groups were carried out using Student's t-test for independent samples and the minimum level of statistical significance was set at P < 0.05. For c-Fos expression, cell counts in the NTC were made from every sixth section throughout the rostrocaudal extent of the nucleus for each rat and its control. In order to avoid differences related to the asymmetrical sectioning of the brain, c-Fos+ cells were counted bilaterally (three sections for each nucleus) (Scion Image Analysis) and the mean value obtained from the two sides was used for the statistical analysis. Student's t-test for unpaired data was used to compare differences in the mean number of c-Fos-immunoreactive nuclei per cell group between controls and treatment groups. A probability level < 5% was regarded as significant.

Results

Confirmation of NTG-induced hyperalgesia

In the vehicle group, the injection of formalin resulted in a highly reliable, typical, biphasic pattern of flinches/shakes of the injected paw, being characterized by an initial acute phase of nociception within the first 5 min, followed by a prolonged tonic response from 15 to 60 min after formalin injection. In keeping with previous observations (17), NTG induced a significant hyperalgesic state that could be detected as an increase in the total number of flinches/shakes in Phase II of the formalin test (Figure 1), to suggest that NTG-induced hyperalgesia is mediated by central (spinal or supraspinal) neuromodulatory mechanisms, rather than by peripheral and purely chemical mechanism.

Figure 1.

Hyperalgesic effect of nitroglycerin (NTG4h) at the formalin test. Histograms represent the total number of flinches and shakes in Phase I (a) and II (b) of formalin test and show that NTG induces hyperalgesia during Phase II of the test. Data are expressed as mean ± s.d. of six animals. *P < 0.05 vs. vehicle group.

FAAH and MAGL activity

NTG administration induced a significant increase in FAAH activity in the medulla and in the hypothalamus, while the activity of both FAAH and MAGL increased in the mesencephalon when compared with the control group (Table 1).

Table 1.

Activity of fatty acid amide hydrolase (FAAH), and of monoacylglycerol lipase (MAGL) in selected cerebral areas of rats

Groups	Cerebral areas
	Medulla	Mesencephalon	Hypothalamus
FAAH activity†
CTRL	165 ± 9	96 ± 9	136 ± 8
NTG 4 h (10 mg/kg)	190 ± 10*	157 ± 16*	159 ± 9*
MAGL activity‡
CTRL	529 ± 9	392 ± 10	492 ± 8
NTG 4 h (10 mg/kg)	513 ± 10	565 ± 11*	453 ± 9

P < 0.05 vs. control group.

†

Substrate was 10 µm ³H-AEA.

‡

Substrate was 10 µm ³H-OG.

Data are expressed as mean ± standard deviation of four animals (pmol min⁻¹ mg⁻¹ protein).

CB receptor binding

The increase in enzymatic activity was associated with a significant increase of ³H-CB receptor binding (Figure 2) in the mesencephalon and in the hypothalamus, whereas no significant change was detected in the medulla.

Figure 2.

Binding of 400 pm 3H-CP55.940 in selected cerebral areas of rat following nitroglycerin (NTG4h) or vehicle (CT) administration. Data are expressed as mean ± s.d. of six animals. *P < 0.05 vs. control group.

c-Fos expression in the nucleus trigeminal is caudalis

In agreement with our previous findings (18,19), NTG administration induced an increase in c-Fos expression in the NTC. Pretreatment with AEA significantly inhibited NTG-induced c-Fos expression in this area (Figure 3).

Figure 3.

c-Fos expression in the nucleus trigeminalis caudalis and its modulation by anandamide treatment. (a) Number of Fos-positive neurons in the group of animals treated with nitroglycerin (NTG4h) or with vehicle (CT) or with anandamide 30 min before nitroglycerin (AEA+NTG). *P < 0.05 vs. NTG4h. (b) Micrographs of representative sections of the nucleus trigeminalis caudalis of rats treated with nitroglycerin (left) or pretreated with anandamide (right) before receiving nitroglycerin.

Discussion

Migraine is a disabling neurological disorder that involves the activation of the trigeminovascular system. NTG administration induces a spontaneous-like migraine attack, with a latency of several hours, and in rat it activates specific cerebral nuclei via the intervention of selected neurotransmitters and neuromediators (17–20). Experimental evidence has shown the antinociceptive action of endocannabinoids and their role in the modulation of trigeminovascular system activation (21). Recently, it was found that AEA and 2-AG levels in platelets are significantly lower in patients with chronic migraine compared with control subjects (22), therefore suggesting a dysfunction of the endocannabinoid system in this disorder.

Endocannabinoids, indeed, exert a critical control on cerebrovascular tone, by interacting with serotonergic transmission, NO production, and CGRP release (3). CB1 receptors seem to be involved in the NO/CGRP cross-talk, which causes headache and dural blood vessel dilation (4). Additionally, endocannabinoids may inhibit 5-HT_2A serotonin receptors, which might make them suitable for the preventive treatment of migraine (23).

CB1 receptors are located in central and peripheral nerve terminals and may regulate the release of both excitatory and inhibitory neurotransmitters when activated (24). In the case of primary sensory neurons, CB1 receptor activation reduces the pathological pain sensation (25–27). In addition to the major role of brain CB1 receptors, there is recent evidence implicating also type-2 cannabinoid (CB2) receptors in the antihyperalgesic activity of cannabinoids in models of acute and chronic, neuropathic pain, especially of inflammatory origin (28).

In this study, we have reported significant changes in the endocannabinoid system in the brainstem and hypothalamus of rat following NTG administration, which induces hyperalgesia and c-Fos expression in the NTC and which was adopted as an experimental model of migraine.

Medulla

In this region, NTG induced a significant increase of FAAH activity, which is indicative of a reduction of AEA levels in this area, associated with an increase in the density of CB binding sites.

It is known that NTG activates brainstem areas implicated in nociception and autonomic functions (17–19). The medulla is the area that contains NTC, one of the most important relay stations for pain transmission in the cephalic area: the observed changes in FAAH, compared with the stability of MAGL, seem to suggest that AEA, rather than 2-AG, is the endocannabinoid more likely to be implicated in the modulation of pain originating in the cephalic area. In agreement with this interpretation, AEA proved to act as an important negative modulator of pain transmission in the superficial layer of NTC, as shown by the reduction that AEA provoked in NTG-induced c-Fos expression in this area. AEA possesses vasodilator activity and it has been identified also in endothelial cells, confirming its potential role in the modulation of the vascular system (29,30). Furthermore, AEA reduces hyperalgesia and inflammation via inhibition of CGRP release in capsaicin-activated nerve terminals (25). Akerman et al. (4) have reported that AEA may act both presynaptically, to prevent CGRP release from trigeminal sensory fibres, and postsynaptically, to inhibit CGRP-induced NO release in the smooth muscle of dural arteries. We have shown that NTG administration induces a sustained (up to 4 h) decrease in CGRP immunoreactivity in NTC, thus suggesting a release of neuropeptide and an important role in the development of pain and hyperalgesia (31). CB1 receptors are localized on fibres in the spinal trigeminal tract and spinal NTC (32). The activation of CB1 receptors in trigeminal neurons after pretreatment with AEA (33) could be responsible for the inhibition of CGRP release from central terminals of primary afferent fibres, therefore reducing NTG-induced c-Fos expression. Against this background, we can hypothesize that the observed increase in FAAH levels in this area may be secondary to the release of AEA in response to NTG-induced CGRP release and hyperalgesia.

Mesencephalon

In the mesencephalon, NTG increased FAAH and MAGL activities, suggesting a reduction in the endogenous levels of both AEA and 2-AG. In fact, an inverse relationship between FAAH activity and AEA levels has been demonstrated in various cells and tissues (34). In line with this, several studies have confirmed the importance of a physiological role for 2-AG and AEA in suppressing pain, suggesting that FAAH and MAGL inhibitors may represent novel therapeutic tools for the treatment of diverse pain disorders by increasing the bioavailability of endogenous cannabinoids (35–37). Previous studies have shown that in the periaqueductal grey, a mesencephalic nucleus important for nociception and a putative migraine generator, endocannabinoid concentrations increase in response to peripheral inflammation (38,39). In the present study, we have reported that the increase of FAAH and MAGL in the mesencephalic area is accompanied by an increase in the density of CB binding sites. Petrosino et al. (40) have previously shown that AEA and 2-AG, operating at both spinal and supraspinal levels, are up-regulated during chronic constriction injury of the sciatic nerve, probably to inhibit pain. In a recent study, it was shown that CB1 receptors are up-regulated in dorsal root ganglion after the development of neuropathic pain (41), and that sciatic nerve injury induces CB1 up-regulation in the spinal cord partly mediated through tyrosine kinase receptors and the mitogen-activated protein kinase (42). Similarly, we can hypothesize that the observed up-regulation of CB binding sites during NTG-induced hyperalgesia is a compensatory mechanism to counteract the reduction of endocannabinoid levels that are released in response to the NTG-induced alteration of the nociceptive system.

Hypothalamus

The hypothalamus is known to modulate different functions and is probably involved in the pathophysiology of a variety of primary headaches, including cluster headache and chronic migraine (43). Recently, it was reported that during the headaches there is significant neuronal activation in the midbrain and pons, but also in the hypothalamus (44).

In the present study, up-regulation of CB binding sites and a significant increase of FAAH activity were found in the hypothalamus following NTG administration, whereas no change in the activity of MAGL was observed. In analogy with the findings obtained in the medulla, AEA emerged as the endocannabinoid involved in NTG-mediated changes, whereas 2-AG did not seem to play any significant role. Anatomical evidence supports the existence of synergistic interactions between the endocannabinoid system and NO in this area. Indeed, experimental evidence suggests a complex functional relationship between NO and hypothalamic–pituitary–adrenal (HPA) axis (45,46). Stress and headache are closely related through multiple ways (47). Nitric oxide synthase-positive neurons in the hypothalamic nucleus express CB1 receptor, confirming that NO and the endocannabinoid system are functionally linked (48). NO formation increases in the hypothalamus following systemically administered NTG, thus facilitating central sympathetic functions (49). NO released/produced by NTG could induce HPA axis activation causing indirectly CB1 up-regulation, as an endogenous defence mechanism of modulation (50).

In conclusion, the findings of this study univocally support a role for AEA and, to a lesser extent, for 2-AG in the modulation of NTG-induced hyperalgesia. Studies are presently underway for evaluating the antinociceptive/antihyperalgesic activity of FAAH and MAGL inhibitors, which may hopefully contribute to identify novel therapeutic targets and tools for the treatment of migraine. The inconsistent pattern observed as regards CB binding densities may depend on differences in terms of affinity in the medulla. Further studies are needed with full characterization of the receptor binding properties with increasing concentrations of ligand.

Footnotes

Acknowledgements

This investigation was supported by a grant of the Italian Ministry of Health (RC 06-07) to R.G., G.S., G.N. and C.T., by the Italian Ministry of University and Research (FIRB 2006), and by Fondazione TERCAS (Research Programs 2004 and 2005) to M.M.

References

Jhaveri

Richardson

Chapman

. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007; 152: 624–32.

Di Marzo

Petrosino

. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007; 18: 129–40.

Pertwee

. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569–611.

Akerman

Kaube

Goadsby

. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther 2004; 309: 56–63.

Cupini

Bari

Battista

Argirò

Finazzi-Agrò

Calabresi

Maccarrone

. Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia 2006; 26: 277–81.

Buzzi

Tassorelli

Nappi

. Peripheral and central activation of trigeminal pain pathways in migraine: data from experimental animal models. Cephalalgia 2003; 23: 1–4.

Tassorelli

Greco

Wang

Sandrini

Nappi

. Prostaglandins, glutamate and nitric oxide synthase mediate nitroglycerin-induced hyperalgesia in the formalin test. Eur J Pharmacol 2006; 534: 103–7.

Wilson

Nicoll

. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410: 588–92.

Wilson

Nicoll

. Endocannabinoid signaling in the brain. Science 2002; 296: 678–82.

10.

McKinney

Cravatt

. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005; 74: 411–32.

11.

Dinh

Carpenter

Leslie

. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002; 99: 10819–24.

12.

Bisogno

Berrendero

Ambrosino

Cebeira

Ramos

Fernandez-Ruiz

Di Marzo

. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 1999; 256: 377–80.

13.

Rouzer

Marnett

. Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids. J Biol Chem 2008; 283: 8065–9.

14.

Centonze

Bari

Rossi

Prosperetti

Furlan

Fezza

. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007; 130: 2543–53.

15.

Maccarrone

Rossi

Bari

De Chiara

Fezza

Musella

. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nature Neurosci 2008; 11: 152–9.

16.

Tjolsen Aberge

Hunskaar

Rosland

Hole

. The formalin test: an evaluation of the method. Pain 1999; 51: 5–17.

17.

Tassorelli

Greco

Wang

Morelli

Nappi

. Nitroglycerin induces hyperalgesia in rats: a Time–Course Study. Eur JPharm 2003; 464: 159–62.

18.

Tassorelli

Greco

Sandrini

Nappi

. Central components of the analgesic/antihyperalgesic effect of nimesulide: studies in animal models of pain and hyperalgesia. Drugs 2003; 63: 9–22.

19.

Tassorelli

Greco

Morazzoni

Riva

Sandrini

Nappi

. Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine. Cephalalgia 2005; 25: 612–21.

20.

Tassorelli

Greco

Armentero

Blandini

Sandrini

Nappi

. A role for brain COX2 and prostaglandine-E2 in migraine: effects of nitroglycerin. Int Rev Neurobiol 2007; 82: 373–82.

21.

Akerman

Holland

Goadsby

. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther 2007; 320: 64–71.

22.

Rossi

Pini

Cupini

Calabresi

Sarchielli

. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol 2008; 64: 1–8.

23.

Russo

. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuro Endocrinol Lett 2004; 25: 31–9.

24.

Ong

Mackie

. A light and electron microscopic study of the CB₁ cannabinoid receptor in primate brain. Neuroscience 1999; 92: 1177–91.

25.

Richardson

Aanonsen

Hargreaves

. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998; 345: 145–53.

26.

Johanek

Heitmiller

Turner

Nader

Hodges

Simone

. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 2001; 93: 303–15.

27.

Rukwied

Watkinson

McGlone

Dvorak

. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003; 100: 283–8.

28.

Ibrahim

Rude

Stagg

Lai

Vanderah

Porreca

. CB2 cannabinoid receptor mediation of antinociception. Pain 2006; 122: 36–42.

29.

Battista

Fezza

Maccarrone

. Endocannabinoids and their involvement in the neurovascular system. Curr Neurovasc Res 2004; 1: 129–40.

30.

Maccarrone

Bari

Lorenzon

Bisogno

Di Marzo

Finazzi-Agrò

. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem 2000; 275: 13484–92.

31.

Greco

Tassorelli

Sandrini

Di Bella

Buscone

Nappi

. Role of calcitonin gene-related peptide and substance P in different models of pain. Cephalalgia 2008; 28: 114–26.

32.

Tsou

Brown

Sañudo-Peña

Mackie

Walker

. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393–411.

33.

Akerman

Kaube

Goadsby

. Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. Br J Pharmacol 2003; 140: 718–24.

34.

Centonze

Battistini

Maccarrone

. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Design 2008; 14: 2370–82.

35.

Hohmann

Suplita

Bolton

Neely

Fegley

Mangieri

. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005; 435: 1108–12.

36.

Suplita

Gutierrez

Fegley

Piomelli

Hohmann

. Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology 2006; 50: 372–9.

37.

Maccarrone

. Fatty acid amide hydrolase: a potential target for next generation therapeutics. Curr Pharm Des 2006; 12: 759–72.

38.

Walker

Huang

Strangman

Tsou

Sanudo-Pena

. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 1999; 96: 12198–203.

39.

Maione

Bisogno

de Novellis

Palazzo

Cristino

Valenti

. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey inhibition of fatty acid amide hydrolase affects descending nociceptive pathaways via both cannabinoid receptor type and transient teceptor potential vanillod type-1 receptors. J Pharmacol Exp Ther 2006; 316: 969–82.

40.

Petrosino

Palazzo

de Novellis

Bisogno

Rossi

Maione

Di Marzo

. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 2007; 52: 415–22.

41.

Mitrirattanakul

Ramakul

Guerrero

Matsuka

Ono

Iwase

. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 2006; 126: 102–14.

42.

Lim

Sung

Mao

. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 2003; 105: 275–83.

43.

Holland

Goadsby

. The hypothalamic orexinergic system: pain and primary headaches. Headache 2007; 47: 951–62.

44.

Denuelle

Fabre

Payoux

Chollet

Geraud

. Hypothalamic activation in spontaneous migraine attacks. Headache 2007; 47: 1418–26.

45.

Seo

Rivier

. Microinfusion of a nitric oxide donor in discrete brain regions activates the hypothalamic–pituitary–adrenal axis. J Neuroendocrinol 2001; 13: 925–33.

46.

Bredt

Snyder

. Nitric oxide, a novel neuronal messenger. Neuron 1992; 8: 3–11.

47.

Nash

Thebarge

. Understanding psychological stress, its biological processes, and impact on primary headache. Headache 2006; 46: 1377–86.

48.

Azad

Marsicano

Eberlein

Zieglgansberger

Spanagel

Lutz

. Differential role of the NO pathway on delta(9)-THC-induced central nervous system effects in the mouse. Eur J Neurosci 2001; 13: 561–8.

49.

Ignarro

Byrns

. Increased nitric oxide concentrations in posterior hypothalamus and central sympathetic function on nitrate tolerance following subcutaneous nitroglycerin. Nitric Oxide 1999; 3: 153–61.

50.

Hill

Sinopoli

Viau

Hillard

Gorzalka

. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic–pituitary–adrenal axis. Neuropsychopharmacology 2006; 31: 2591–9.